High Pointe Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

High Pointe Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,200	Closed	-$824K	–	94
2020 Q3	$824K	Sell	7,200 -150	-2%	-$16.2K	1%	45
2020 Q2	$825K	Hold	7,350	–	–	1.08%	39
2020 Q1	$660K	Buy	7,350 +300	+4%	+$29.4K	0.94%	43
2019 Q4	$762K	Sell	7,050 -1,650	-19%	-$176K	0.9%	48
2019 Q3	$852K	Hold	8,700	–	–	1.17%	36
2019 Q2	$1.14M	Buy	+8,700	New	+$1.12M	1.6%	22

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

High Pointe Capital Management's ALXN Position: Q4 2020 in Review

High Pointe Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 7,200 shares — an estimated $824K sold.

High Pointe Capital Management first reported a position in ALXN in Q2 2019 and held it in 6 quarters. The position peaked at $1.14M in Q2 2019. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

High Pointe Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
High Pointe Capital Management sold 7,200 Alexion Pharmaceuticals shares in Q4 2020, an estimated $824K.
High Pointe Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 6 quarters.
High Pointe Capital Management's Alexion Pharmaceuticals position peaked at $1.14M in Q2 2019.
825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on High Pointe Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.